Divarasib for Non-Small Cell Lung Cancer

(KRASCENDO 3 Trial)

This trial tests a new treatment called divarasib for individuals with KRAS G12C-positive non-small cell lung cancer (NSCLC). The researchers aim to determine if divarasib outperforms current options, such as pembrolizumab, nivolumab, or observation after surgery. The trial seeks participants who have undergone surgery to remove lung cancer but did not achieve a complete response to pre-surgery chemotherapy combined with immunotherapy. Suitable candidates include those with NSCLC who have had surgery and a confirmed KRAS G12C mutation in their cancer. As a Phase 3 trial, this study serves as the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking treatment advancements.

Research has shown that divarasib is generally well-tolerated by patients with KRAS G12C-positive non-small cell lung cancer. In an earlier study, 61 out of 65 patients experienced at least one treatment-related side effect, but only 11 faced severe side effects. Importantly, no life-threatening side effects occurred. Other studies confirm divarasib's consistent safety record, with no new safety concerns identified in recent trials. This suggests that while divarasib is manageable for most people, it still carries some risks.¹²³⁴⁵

Divarasib is unique because it specifically targets certain genetic mutations in non-small cell lung cancer (NSCLC) that current treatments may not address as effectively. Unlike standard immunotherapies like pembrolizumab or nivolumab, which stimulate the immune system to fight cancer, Divarasib directly inhibits the abnormal proteins driving cancer growth. This targeted approach could offer a more precise treatment, potentially leading to better outcomes for patients with these specific mutations. Researchers are excited because Divarasib's novel mechanism of action might provide an option for patients who do not respond well to existing therapies.

Research has shown that divarasib, which participants in this trial may receive, is a promising treatment for non-small cell lung cancer (NSCLC) with a specific KRAS mutation. In one study, divarasib shrank tumors in over half of the patients, achieving a 52% response rate. Additionally, 89% of patients had their disease well-managed, meaning the cancer remained under control. On average, patients lived about 13.1 months without their cancer worsening. These results suggest that divarasib could be an effective option for treating this type of lung cancer.¹²⁵⁶⁷